ELI LILLY AND CO

LLY | New York Stock Exchange
Business Summary
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Country of Incorporation
United States of America
Incorporation Date
1901-01-17
Business Sector
Pharmaceuticals & Medical Research
Company Address
Lilly Corporate Ctr, Drop Code 1094
Get access to the below data and more business development tools by signing up for the MENA Company Data product.
- Ownership details
- Corporate structure
- Business classification
- Officers & Directors contact details
- Full company contact details
Find out more
Multiply your reach by contributing your content to LSEG
LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.

NEWS ON THIS COMPANY

Find companies

ZAWYA NEWSLETTERS

Get insights and exclusive content from the world of business and finance that you can trust, delivered to your inbox.

Subscribe to our newsletters: